Lead Sponsor

Alexion Pharmaceuticals, Inc.

Age

All ages

Sex

ALL

Healthy Volunteers

No

•Diagnosis of gMG confirmed by a positive serologic test for anti-AChR antibodies (Abs) obtained at Screening and/or during Screening Period
•Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of Class II to Class IV at Screening
•Participants receiving treatment must be on a stable dosing regimen of adequate duration prior to Screening and during the Screening Period.
•Eculizumab-experienced participants must have been enrolled and treated with eculizumab in Study ECU-MG-303 for at least 6 months (180 days) and must have been on a stable dose for ≥ 2 months (60 days) prior to Screening.
•All participants must be vaccinated against meningococcal infection

•Medical Conditions
•Any untreated thymic malignancy, carcinoma, or thymoma.
•Participants with a history of treated benign thymoma
•History of thymectomy, thymomectomy, or any thymic surgery within the 12 months prior to Screening
•History of N meningitidis infection
•Known to be human immunodeficiency virus (HIV) positive
•History of unexplained infections
•Known or suspected history of drug or alcohol abuse or dependence within 1 year prior to the start of the Screening Period

Related studies

NCT06312644 · Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, and more

NCT07247279 · Rare Diseases, Generalized Myasthenia Gravis (gMG)

NCT06055959 · Generalized Myasthenia Gravis

NCT06149559 · Generalized Myasthenia Gravis

NCT04833894 · Generalized Myasthenia Gravis

Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis